While conventional microbiological methods may require 2-4 days to produce bacterial identification and susceptibility results, VERIGENE BC-GP provides results within 2.5 hours of blood culture positivity.
Gram-positive bacteria are also a common source of contamination during blood draws, which results in clinically-irrelevant positive blood cultures. This can lead to inappropriate antimicrobial use1 and wasted time and cost. Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods.
|Streptococcus anginosus Group||•||•|
|Automation||Sample to Result|
|Instrumentation||VERIGENE Reader and Processor SP|
|Workflow||On-Demand and Scalable|
|Sample Type||Positive Blood Culture Bottle†|
|Hands-On Time||<5 minutes|
|Run Time||<2.5 hours|
|†For use with all commercially available continuous monitoring blood culture bottles; see VERIGENE BC-GP package insert for details.|
VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IVD) – Product Information
Impact of Rapid Molecular Testing of Gram-Positive Blood Culture Isolates Using VERIGENE Gram-Positive Blood Culture on Antimicrobial Stewardship and Clinical Outcomes within a Community Health System – Poster
Impact of Rapid Molecular Testing of Gram-Positive Blood Culture Isolates Using VERIGENE Gram-Positive Blood Culture (BC-GP) on Antimicrobial Stewardship and Clinical Outcomes within a Community Health System – Abstract
Learn how the VERIGENE® System provides cost-effective bacterial identification and antibiotic resistance determination directly from positive blood culture bottles up to 48 hours faster than conventional methods.
For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions. Please contact Luminex at [email protected] to obtain the appropriate product information for your country of residence.
The VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) performed using the sample-to-result VERIGENE System is a qualitative, multiplexed in vitro diagnostic test for the simultaneous detection and identification of potentially pathogenic gram-positive bacteria which may cause bloodstream infection (BSI). BC-GP is performed directly on blood culture bottles identified as positive by a continuous monitoring blood culture system and which contain gram-positive bacteria.
BC-GP detects and identifies the following bacterial genera and species: Staphylococcus spp., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus spp., Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group, Enterococcus faecalis, Enterococcus faecium, Listeria spp.
In addition, BC-GP detects the mecA resistance marker, inferring mecA-mediated methicillin resistance, and the vanA and vanB resistance markers, inferring vanA/vanB-mediated vancomycin resistance. In mixed growth, BC-GP does not specifically attribute van-mediated vancomycin resistance to either E. faecalis or E. faecium, or mecA-mediated methicillin resistance to either S. aureus or S. epidermidis.
BC-GP is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial bloodstream infections; however, is not to be used to monitor these infections. Sub-culturing of positive blood cultures is necessary to recover organisms for susceptibility testing, identification of organisms not detected by BC-GP, differentiation of mixed growth, association of antimicrobial resistance marker genes to a specific organism, or for epidemiological typing.